



**6. Utilization Management Policy Review\***

- Enhanced Opioid Management
  - Opioids ER Step Therapy & Limits
  - Opioids IR Acute Pain Duration & Quantity Limit
  - Opioid IR Combo Acute Pain Duration Limit
  - Opioid IR Combo Quantity Limit
  - Xartemis® XR Limit Policy
- Specialty Drug Management Strategies
- Long Acting Insulin & GLP-1 Agonist Combo Policy
- Vytorin® 10-80 Zocor® 80 ST Policy
- Lyrica®, Gralise®, Horizant® ST Policy
- Existing Policies
  - Tysabri® SGM
  - Feiba® SGM
  - Rituxan Hycela® SGM
  - Lynparza® SGM
  - Epogen®, Procrit® SGM
  - Ibrance® SGM
  - Alecensa® SGM
  - Uptravi® SGM
  - Prolia® SGM
  - Makena® SGM
  - Simponi® SGM
  - Remicade®, Inflectra®, Renflexis® SGM
  - Otezla® SGM
  - Orencia® SGM
  - Praluent® SGM
  - Cimzia® SGM
  - Cosentyx® SGM

**7. Executive Closed Session (if necessary)**

**8. Adjourn**

- Next Meeting: TBD

Carl Antolick III, Chair  
Heather Renee Jarnigan, CVS  
Michael Spiritos, MD  
Joseph Shanahan, MD  
Jennifer Burch, PharmD, CDE  
Jennifer Burch, PharmD, CDE  
Jennifer Burch, PharmD, CDE  
Carl Antolick III, Chair  
Jennifer Burch, PharmD, CDE  
Jennifer Burch, PharmD, CDE  
David Konanc, MD

David Konanc, MD  
David Konanc, MD  
Michael Spiritos, MD  
Michael Spiritos, MD  
Michael Spiritos, MD  
Michael Spiritos, MD  
Michael Spiritos, MD  
John Anderson, MD  
John Anderson, MD  
John Anderson, MD  
Joseph Shanahan, MD  
Joseph Shanahan, MD  
Joseph Shanahan, MD  
Joseph Shanahan, MD  
Jennifer Burch, PharmD, CDE  
Jennifer Burch, PharmD, CDE  
Jennifer Burch, PharmD, CDE  
Carl Antolick III, Chair  
Carl Antolick III, Chair

\*Requires a recommendation from the P&T Committee